Combination therapy with losartan and L-carnitine protects against endothelial dysfunction of streptozotocin-induced diabetic rats

Eur J Pharmacol. 2014 Dec 5:744:10-7. doi: 10.1016/j.ejphar.2014.09.032. Epub 2014 Oct 2.

Abstract

Endothelial dysfunction is a critical factor during the initiation of diabetic cardiovascular complications and angiotensin II appears to play a pivotal role in this setting. The present study aimed to investigate whether the combination therapy with losartan and the nutritional supplement, L-carnitine can provide an additional protection against diabetes-associated endothelial dysfunction and elucidate the possible mechanism(s) underlying this effect. Diabetes was induced by intraperitoneal injection of streptozotocin (STZ) (60 mg/kg) in rat. Effects of losartan (20 mg/kg, orally, 3 months) and L-carnitine (200 mg/kg, orally, 3 months) on tumor necrosis factor (TNF)-α, oxidative stress parameters, endothelial nitric oxide synthase expression (eNOS), and vascular function were evaluated. Our results showed a marked increase in aortic superoxide anion (O2(-)) production and serum malondialdehyde (MDA) level alongside attenuating antioxidant enzyme capacities in diabetic rats. This was associated with a significant increase in anigiotensin II type 1 receptor gene expression and TNF-α serum level of diabetic rats alongside reducing aortic eNOS gene expression and nitric oxide (NO) bioavailability. The single or combined administration of losartan and L-carnitine significantly inhibited these changes. Additionally, the vascular endothelium-dependent relaxation with acetylcholine (ACh) in aortic diabetic rat was significantly ameliorated by the single and combined administration of losartan or L-carnitine. Noteworthy, the combination therapy exhibited a more profound response over the monotherapy. Collectively, our results demonstrate that the combined therapy of losartan and L-carnitine affords additive beneficial effects against diabetes-associated endothelial dysfunction, possibly via normalizing the dysregulated eNOS and reducing the inflammation and oxidative stress in diabetic rats.

Keywords: Diabetes; Endothelial dysfunction; Losartan; Oxidative stress; l-carnitine.

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Aorta / drug effects
  • Aorta / metabolism
  • Carnitine / pharmacology*
  • Diabetes Mellitus, Experimental / chemically induced*
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Drug Therapy, Combination / methods
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Losartan / pharmacology*
  • Male
  • Malondialdehyde / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects
  • Protective Agents / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Angiotensin / metabolism
  • Streptozocin / pharmacology*
  • Superoxides / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Protective Agents
  • Receptors, Angiotensin
  • Tumor Necrosis Factor-alpha
  • Vasodilator Agents
  • Superoxides
  • Nitric Oxide
  • Malondialdehyde
  • Streptozocin
  • Nitric Oxide Synthase Type III
  • Losartan
  • Acetylcholine
  • Carnitine